History
Epitype GmbH is a spin-off of the University women’s hospital Jena, Germany.
Epitype was originally founded as oncgnostics GmbH in early 2012 as a spin-off from the Department of Gynecology at Jena University Hospital. The foundation for the company was laid within the EU joint project INCA (Infections and Cancer), through research on epigenetic markers involved in the development of cervical cancer in the Department of Gynecological Molecular Biology led by Prof. Dürst. A successful EXIST research transfer project enabled the preparation for the company’s launch.
Driven by the goal of improving early detection of cervical cancer, the molecular diagnostic test GynTect® was developed and has been available on the market since 2015. The cancer tests developed by the company are used in cancer screening and diagnostics. Since 2025, operating as Epitype GmbH, the company has been further advancing the broad application of its innovations.
Since 05. 2021, Epitype has its office and labs in the industrial park in the north of Jena. Before that, Epitype was located at the Beutenbergcampus Jena
Epigenetic markers for fast and reliable cervical cancer diagnostics, the application of which we have patented, provided the basis for the development of GynTect, our first diagnostic test, which may be used in early detection, therapy decision and post-surgical care. We plan to patent markers for applications in further diagnostic fields.
Research and development as well as the management are certified according to ISO 13485 since early 2013.